Exacerbations as a starting point of pro-active chronic obstructive pulmonary disease management

Respiratory Medicine

Volumn 99, Issue 12, 2005, Pages 1568-1575

  Zoia, Maria C ^a   Corsico, Angelo G ^a   Beccaria, Massimiliano ^a   Guarnone, Roberta ^a   Cervio, Gabriella ^a   Testi, Renato ^a   Bressan, Maria A ^a   Pozzi, Ernesto ^a   Cerveri, Isa ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Primary care; Underdiagnosis; Undertreatment

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; LONG ACTING DRUG; MUCOLYTIC AGENT; OXYGEN; STEROID; THEOPHYLLINE;

ADULT; AGED; ARTERIAL GAS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT INFORMATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SPIROMETRY; TREATMENT FAILURE; TREATMENT PLANNING;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC ERRORS; EMERGENCIES; FEMALE; HOSPITALIZATION; HUMANS; LUNG; MALE; MIDDLE AGED; PATIENT SELECTION; PROBABILITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT FAILURE;

EID: 28044447233     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.03.032     Document Type: Article

References (34)

1. G. van den Boom C.P. van Schayck M.P. van Mollen et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program Am J Respir Crit Care Med 158 1998 1730-1738
2. G.J. Huchon A. Vergnenegre F. Neukirch G. Brami N. Roche P.M. Preux Chronic bronchitis among French adults: High prevalence and underdiagnosis Eur Respir J 20 2002 806-812
3. D.B. Coultas D. Mapel R. Gagnon E. Lydick The health impact of undiagnosed airflow obstruction in a national sample of United States adults Am J Respir Crit Care Med 164 2001 372-377
4. M. Lindstrom E. Jonsson K. Larsson B. Lundback Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden Int J Tuberc Lung Dis 6 2002 76-84
5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; Update of the Management Sections, GOLD website (www.goldcopd.com). Updated: 1 July 2003.
6. Strategies in preserving lung health and preventing COPD and associated diseases The National Lung Health Education Program (NLHEP) Chest 113 2 Suppl 1998 123s-163s
7. D. Zaas R. Wise C. Wiener Longcope spirometry investigation team. airway obstruction is common but unsuspected in patients admitted to a general medicine service Chest 125 2004 106-111
8. S. Burge J.A. Wedzicha COPD exacerbations: Definitions and classifications Eur Respir J 21 supp. 41 2003 46s-53s
9. D.A. Mahler The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease J Allergy Clin Immunol 110 2002 298s-303s
10. V. Brusasco R. Hodder M. Miravitlles L. Korducki L. Towse S. Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 2003 399-404
11. P.S. Burge P.M. Calverley P.W. Jones S. Spencer J.A. Anderson T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial BMJ 320 2000 1297-1303
12. R. Rodriguez-Roisin Toward a consensus definition for COPD exacerbations Chest 117 2000 398s-401s
13. Standardization of Spirometry 1994 Update. American Thoracic Society Am J Respir Crit Care Med 152 1995 1107-1136
14. P.H. Quanjer G.J. Tammeling J.E. Cotes O.F. Pedersen R. Peslin J.C. Yernault Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society Eur Respir J Suppl 16 1993 5-40
15. J.C. Bestall E.A. Paul R. Garrod R. Garnham P.W. Jones J.A. Wedzicha Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease Thorax 54 1999 581-586
16. M. Cazzola M.G. Matera Long-acting bronchodilators are the first-choice option for the treatment of stable COPD Chest 125 2004 9-11
17. R.A. Incalzi L. Fuso M. Serra et al. Exacerbated chronic obstructive pulmonary disease: A frequently unrecognized condition J Intern Med 252 2002 48-55
18. D.D. Sin F.A. McAlister S.F. Man N.R. Anthonisen Contemporary management of chronic obstructive pulmonary disease: Scientific review JAMA 290 2003 2301-2312
19. P.M. Calverley P. Walker Chronic obstructive pulmonary disease Lancet 362 2003 1053-1061
20. M.R. Partridge Written asthma action plans Thorax 59 2004 87-88
21. D. Gorecka M. Bednarek A. Nowinski E. Puscinska A. Goljan-Geremek J. Zielinski Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate Chest 123 2003 1916-1923
22. D.A. Mahler J.F. Donohue R.A. Barbee et al. Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957-965
23. S.I. Rennard W. Anderson R. ZuWallack et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087-1092
24. E.R. Sutherland H. Allmers N.T. Ayas A.J. Venn R.J. Martin Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis Thorax 58 2003 937-941
25. W. Szafranski A. Cukier A. Ramirez et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74-81
26. S.F. Man F.A. McAlister N.R. Anthonisen D.D. Sin Contemporary management of chronic obstructive pulmonary disease. Clinical applications JAMA 290 2003 2313-2316
27. N.M. Siafakas P. Vermeire N.B. Pride et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force Eur Respir J 8 1995 1398-1420
28. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial Ann Intern Med 93 1980 391-398
29. T.M. Wilkinson G.C. Donaldson J.R. Hurst T.A. Seemungal J.A. Wedzicha Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 169 2004 1298-1303
30. P. Paggiaro Does early treatment of exacerbation improve outcome in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 169 2004 1267-1268
31. S.D. Sullivan S.D. Ramsey A.L. Todd The economic burden of COPD Chest 117 2000 5s-9s
32. E.F. Wouters Economic analysis of the Confronting COPD survey. An overview of results Respir Med 97 suppl C 2003 s3-s14
33. R. Dal Negro A. Rossi I. Cerveri The burden of COPD in Italy: Results from the Confronting COPD survey Respir Med 97 2003 s43-s50
34. World Health Organization. Website on mortality: http://www.who.int/whosis/mort/index.html.